Biotech companies at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
31 biotech companies are at Antibody Engineering 2026 — 43 presentations on the program. Most represented: Xencor (4 on the program), Rondo Therapeutics (2 on the program), argenx (2 on the program). 7 of them have their own page in this guide. As of Sep 26, 2026.
Topic
Top represented
Showing 1–16 of 31 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Xencor Pasadena, CA | |
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases. | Talk Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 4:15pm–5:00pm Talk Mon Dec 14 8:00am–8:05am Talk Mon Dec 14 10:55am–11:30am Talk Wed Dec 16 8:10am–8:15am Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics |
RT Rondo Therapeutics Hayward, CA | |
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors. | Talk Tue Dec 15 2:25pm–2:30pm Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Talk Wed Dec 16 8:10am–8:15am |
Immunology company developing antibody-based medicines for autoimmune diseases, with marketed FcRn-blocking therapy. | Talk Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. Talk Wed Dec 16 4:15pm–4:45pm A Novel Antibody Approach to Pan-subclass IgG Reduction An antibody that sweeps up and destroys every subtype of the main antibody class in blood, for diseases caused by self-attacking antibodies. Beyond oncology |
Genmab Copenhagen, Denmark | |
Danish antibody company with marketed cancer medicines, developing bispecific antibodies and antibody-drug conjugates. | Talk Tue Dec 15 2:25pm–2:30pm Talk Wed Dec 16 11:30am–12:00pm Enabling Polyclonal Antibody Production through Fc-engineering of Mutual Exclusive CH3 Interfaces Reshaping the region where two antibody halves join, so several different antibodies can be made together in one mixture without mismatching. |
Gyes Naarden, Netherlands | |
Dutch biotech building multispecific antibodies that act only on cells co-expressing target combinations, for cancer and immune diseases. | Talk Mon Dec 14 8:00am–8:05am Talk Wed Dec 16 2:10pm–2:15pm |
Develops multispecific antibody therapeutics and antibody–drug conjugates using its Azymetric bispecific and other protein engineering platforms. | Talk Sun Dec 13 1:45pm–2:15pm Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers What to get right, from target choice to safety testing, when building T-cell-recruiting antibodies with a built-in second signal. Bispecifics & multispecifics Talk Wed Dec 16 8:45am–9:15am Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability Antibodies that bind three things at once to give T cells an extra activating signal inside solid tumors. Developability & CMC |
Talk Sun Dec 13 11:00am–11:45am Talk Mon Dec 14 2:25pm–2:30pm | |
AB Amberstone Biosciences | |
Preclinical oncology company developing pH-gated, tumor-activated T-cell engagers on its T-MATE platform. | Talk Tue Dec 15 5:45pm–6:15pm Rewriting the Safety–Efficacy Balance: Engineering Conditionally Activated TCEs for Solid Tumors. T-cell-recruiting antibodies switched on by the slightly acidic conditions inside solid tumors and quiet in healthy tissue. |
AV Atlas Venture NewCo | |
Talk Sun Dec 13 1:00pm–1:15pm | |
BigHat Biosciences San Mateo, CA | |
Designs antibody therapeutics with machine learning and a high-throughput wet lab; runs its own pipeline and pharma partnerships. | Talk Tue Dec 15 5:15pm–5:45pm Machine Learning Guided Design of Avidity- and Logic-Gated T Cell Engagers Using machine learning to tune binding strength so T-cell-recruiting antibodies act on diseased cells and spare healthy ones. AI & computational design |
C Chennaibio San Carlos, CA | |
Talk Tue Dec 15 8:45am–9:15am | |
Commit Biologics Aarhus, Denmark | |
Aarhus University spin-out developing bispecific complement-engaging antibodies for cancer and autoimmune disease. | Keynote Mon Dec 14 9:15am–9:50am The Evolution of Antibody Therapies in Autoimmunity: From Toxic Immunosuppressant to Precision Modulator of Disease How antibody drugs for autoimmune disease moved from broadly damping the immune system to targeting single faulty pathways. Beyond oncology |
Divergence Labs New York, NY | |
Drug developer combining computational models and lab work to discover medicines, with ophthalmology programs in its pipeline. | Talk Mon Dec 14 3:00pm–3:30pm One-Shot Antibody Design with AI: Are We There Yet? An assessment of how much of computer-designed antibody discovery really works today, and what still does not. AI & computational design |
Develops bispecific antibodies for immunology and inflammation using its DualScreen discovery engine. | Talk Wed Dec 16 8:10am–8:15am |
EvolveImmune Therapeutics Branford, CT | |
Develops T cell engagers with built-in co-stimulation for solid tumors. | Talk Tue Dec 15 3:30pm–4:00pm Next-Generation Multi-Antigen EVOLVE T Cell Engager with Integrated CD2 Co-stimulation An antibody that grips two tumor markers at once and gives T cells an extra activating signal so the attack stays on target. |
Hummingbird Bioscience Singapore | |
Develops antibody therapeutics and antibody-drug conjugates for cancer and autoimmune diseases. | Talk Wed Dec 16 5:15pm–5:45pm Novel, Next-generation ADCs for Autoimmune and Inflammatory Diseases How antibodies carrying a drug payload could be aimed at the immune cells driving inflammation, not just at cancer. Beyond oncology |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction